Prof. Dr. Rainer Fietkau

Lehrstuhl für Strahlentherapie

Baseline Quality of Life of Physical Function Is Highly Relevant for Overall Survival in Advanced Rectal Cancer (2022) Fitz T, Sörgel C, Rutzner S, Hecht M, Fietkau R, Distel L Journal article Influence of gender on radiosensitivity during radiochemotherapy of advanced rectal cancer (2022) Schuster B, Hecht M, Schmidt M, Haderlein M, Jost T, Büttner-Herold M, Weber K, et al. Journal article The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma (2022) Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, et al. Journal article, Review article Extracranial temporal bone paragangliomas: Re-defining the role of otologic surgery within the scope of function-preserving multimodal concepts (2022) Mantsopoulos K, Thimsen V, Eisenhut F, Weissmann T, Putz F, Fietkau R, Iro H, et al. Journal article Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required (2021) Hecht M, Fietkau R, Gaipl U Journal article, Editorial A Comparison of Single- and Multiparametric MRI Models for Differentiation of Recurrent Glioblastoma from Treatment-Related Change (2021) Eisenhut F, Engelhorn T, Arinrad S, Brandner S, Coras R, Putz F, Fietkau R, et al. Journal article An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma (2021) Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel ME, et al. Journal article Die Bedeutung der Strahlentherapie im Kontext immer effektiver werdender Systemtherapien beim metastasierten NSCLC – Hinweise aus einer Rezidivanalyse nach Immuncheckpointinhibitoren (2021) Schubert P, Fietkau R, Hecht M Journal article Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites? (2021) Weissmann T, Höfler D, Hecht M, Semrau S, Haderlein M, Filimonova I, Frey B, et al. Journal article Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors (2021) Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, et al. Journal article